Circulating levels of osteoprotegerin and receptor activator of NF-κB ligand in patients with chronic renal failure

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 11, 2007, Pages 1498-1503

  Shaarawy, Mohamed ^a   Fathy, Shadia A ^b   Mehany, Nagy L ^c   Hindy, Odette W ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b Ain Shams University   (Egypt)

^c Egyptian Atomic Energy Authority   (Egypt)

Author keywords

Bone mineral density; Chronic renal failure; Markers of bone remodeling; Osteoprotegerin; Receptor activator of nuclear factor B ligand

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; CYSTATIN C; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HEMODIALYSIS; HUMAN; LUMBAR SPINE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; BONE DENSITY; CYSTATINS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LIGANDS; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPROTEGERIN; RANK LIGAND;

EID: 35748985569     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.306     Document Type: Article

References (34)

1. Coen G, Ballanti P, Balducci A, Calabria S, Fischer MS, Jankovic L, et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002;17:233-8.
2. Duarte ME, Peixoto AL, Pacheco AS, Peixoto AV, Rodriguez RD, Lugon JR, et al. The spectrum of bone disease in 200 chronic hemodialysis patients: a correlation between clinical, biochemical and histological findings. Rev Paul Med 1998;116:1790-7.
3. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kid Dis 2002;39:580-6.
4. Shih MS. Osteodystrophy of diabetics in chronic dialysis. A histomorphometric study. Calcif Tissue Int 1989;44:298-9.
5. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid - mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-50.
6. Coen G, Ballanti P, Bonucci E. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998;13:2294-302.
7. Salusky IB, Kuizon BD, Belin TR. Intermittent calcitriol therapy in secondary hyperparathyroidism: comparison between oral and intraperitoneal administration. Kidney Int 1998;54:907-14.
8. Pecovnik Balon B, Bren A. Bone histomorphometry is still the golden standard for diagnosing renal osteodystrophy. Clin Nephrol 2000;54:463-9.
9. Bordier PH, Miravet L, Hioco D. Measure histologique de la mass et de la resorption des travees osseouses. Pathol Biol (Paris) 1964;12:1238-43.
10. Heaf JG, Joffe P, Podenphant J, Andersen JR. Non-invasive diagnosis of uremic osteodystrophy: uses and limitations. Am J Nephrol 1987;7:203-11.
11. Gerakis A, Hutchison AJ, Apostolou T, Freemont AJ, Billis A. Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996;11:2430-8.
12. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J Nephrol 2000;13:437-43.
13. Franke S, Lehmann G, Abendroth K, Hein G, Stein G. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur J Med Res 1998;3:81-8.
14. Monier-Faugere MC, Malluche HH. Role of cytokine in renal osteodystrophy. Curr Opin Nephrol Hypertens 1997;6:327-32.
15. Gonzales EA. The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy. Nephrol Dial Transplant 2000;15:945-50.
16. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991;39:954-60.
17. Montalban C, Garcia-Unzueta MT, De Francisco AL, Amado JA. Serum interleukin-6 in renal osteodystrophy: relationship with PTH and bone remodeling markers. Horm Metab Res 1999;31:14-7.
18. Chambers TJ. Regulation of the differentiation and function of osteoclasts. J Pathol 2000;192:4-13.
19. Hofbauer LC, Lacey DL, Dunstan CR, Spelberg TC, Riggs BL, Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-9.
20. Kong YY, Feige U, Sarosi I. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9.
21. Walsh MC, Choi X. Biology of the TRANCE axis. Cytokine Growth Factor Rev 2003;14:251-63.
22. Franchimont N, Reemaers C, Lambert C, Belaiche J, Bours V, Malaise M, et al. Increased expression of receptor activator of NF-κB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004;138:491-8.
23. Simonet WS, Lacey DL, Dunstan CR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
24. Mizuno A, Amizuka N, Irie K. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-5.
25. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001;79:243-53.
26. Theill LE, Boyle WJ, Penninger JM. RANKL and RANK: T cells bone loss and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
27. Oh KW, Rhee EJ, Lee WY, Kim SW, Baek KH, Kang MI, et al. Circulating osteoprotegerin and receptor activator of NF-κB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol 2005;62:92-8.
28. Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G. A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 2001;37:1247-52.
29. Hofbauer LC, Schoppet M. Serum measurement of osteoprotegerin - clinical relevance and potential application. Eur J Endocrinol 2001;145:681-3.
30. Lee SK, Lorenzo JA. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552-61.
31. Shaarawy M, Mehany NL, Fathy SH, Gadalla MG. Serum cystatin C as a reliable biomarker for assessment of renal function in bilharzial patients with chronic renal failure. Arab J Lab Med 2006;32:75-87.
32. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function. Am J Kidney Dis 2002;40:221-6.
33. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001;86:3162-5.
34. Khosla S, Arrighi HM, Melton LJ. Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002;13:394-9.